Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Stocks to Buy or Sell. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks to buy and sell highlighted in Jim Cramer’s latest calls. Jim ...

A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an acquisition target. During his discussion, Holz suggested that Viking could ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... more specifically small-than-expected tariffs that could grow bigger if countries don’t play ball.

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... some are shorter weeks. Some are bigger. . . what really matters? Boom, Eli Lilly’s scripts are way up.

I see that Novo Nordisk is cheaper than its main competitor ... clear signs of a turnaround in investor sentiment. Don't get me wrong. In the long term, I believe the company is a solid buy.

Therefore, NVO looks like a no-brainer 'Strong buy' opportunity for me. Novo Nordisk is a global healthcare ... company's EBITDA increases even faster than revenue. Data by YCharts NVO is well ...

Novo Nordisk A/S’s blockbuster drug Wegovy was ... 17.5% reduction among people who got a standard dose — but was less than either the highest dose of Eli Lilly & Co.’s Zepbound or the ...

After a disappointing trial of a new Novo Nordisk drug last month and lower-than-expected sales figures ... the wrong debate and the pie is a lot bigger? There’s a huge range, no one knows ...